Compounds > deamino-arginine-vasopressin

deamino-arginine-vasopressin and Jejunal-Diseases

deamino-arginine-vasopressin has been researched along with Jejunal-Diseases* in 1 studies

Other Studies

1 other study(ies) available for deamino-arginine-vasopressin and Jejunal-Diseases

Article	Year
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2001, Volume: 12, Issue:3 A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel. Frequent blood transfusions were required. She started home treatment with recombinant activated factor VII (rFVIIa) at the onset of bleeding, in addition to her standard therapy. From then on, bleeds could be controlled rapidly and no more blood transfusions were needed. We conclude that rFVIIa is effective in this case of angiodysplasia and might be a therapeutic option in similar patients. Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogens; Factor VIIa; Factor VIII; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Iron; Jejunal Diseases; Melena; Middle Aged; Omeprazole; Recombinant Proteins; Recurrence; Tranexamic Acid; Treatment Outcome; von Willebrand Diseases; von Willebrand Factor	2001

Article

Year

Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2001, Volume: 12, Issue:3

A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel. Frequent blood transfusions were required. She started home treatment with recombinant activated factor VII (rFVIIa) at the onset of bleeding, in addition to her standard therapy. From then on, bleeds could be controlled rapidly and no more blood transfusions were needed. We conclude that rFVIIa is effective in this case of angiodysplasia and might be a therapeutic option in similar patients.

Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogens; Factor VIIa; Factor VIII; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Iron; Jejunal Diseases; Melena; Middle Aged; Omeprazole; Recombinant Proteins; Recurrence; Tranexamic Acid; Treatment Outcome; von Willebrand Diseases; von Willebrand Factor

2001